688117.SH
圣诺生物
SSE · Healthcare · Drug Manufacturers - Specialty & Generic · CN
CNY 24.20
−6.17%Year over year
Reported trailing growth
- Revenue
- +49.4%
- EBITDA
- —
- EBIT
- +123.0%
- EPS
- +82.6%
- Free cash flow
- +107.5%
- Operating cash flow
- +571.4%
Forward estimates
Based on analyst estimates
- Revenue
- -65.7%
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- +23.3%
- EBITDA
- +38.5%
- EBIT
- +40.5%
- Net income
- +34.8%
- EPS
- +19.9%
- Free cash flow
- +114.7%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026